JAMA Oncology

04/04/2026

Clonal hematopoiesis of indeterminate potential (CHIP) was associated with increased risk of trastuzumab-related cardiotoxic effects among patients with in both a large UK Biobank cohort and an independent cohort from Seoul National University Hospital.

CHIP positivity was associated with higher incidence of heart failure and cardiotoxic events by multiple clinical definitions.

https://ja.ma/4sT4TfA

04/03/2026

Pretreatment magnetic resonance imaging (MRI) parameters including extraprostatic extension and seminal vesicle invasion were independently associated with higher risk of biochemical recurrence, metastatic failure, and prostate cancer-specific mortality among men undergoing radical prostatectomy.

Quantitative MRI features such as Prostate Imaging Reporting and Data System score, tumor diameter, and apparent diffusion coefficient also provided prognostic value for recurrence, even after adjusting for clinicopathologic factors. These findings confirm that prostate MRI adds independent prognostic information for long-term outcomes in men treated with radical prostatectomy.



https://ja.ma/41JRLNL

04/03/2026

The addition of camrelizumab to chemotherapy produced statistically significant and clinically meaningful 5-year OS benefits compared with chemotherapy alone in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma. https://ja.ma/4s5ajCT

04/02/2026

Low-dose aspirin in older adults was not associated with lower incidence over 8.6 years, and cancer mortality risk did not persist beyond the exposure period. https://ja.ma/4dYHggV

04/01/2026

Among patients with immune checkpoint inhibitor–related cutaneous adverse events, dupilumab therapy was associated with lower 5-year mortality compared to no dupilumab or systemic corticosteroids. https://ja.ma/4tkLDr8

04/01/2026

In the BRIGHT-2 phase 3 randomized clinical trial, bireociclib plus fulvestrant significantly prolonged median progression-free survival for patients with hormone receptor–positive, ERBB2-negative advanced after prior endocrine therapy progression, compared to placebo plus fulvestrant. Improvements in objective response rate and disease control rate were observed for bireociclib-treated patients.

Safety outcomes were consistent with other cyclin-dependent kinase 4/6 inhibitors, including manageable rates of diarrhea and neutropenia. These findings support bireociclib plus fulvestrant as a treatment option for advanced breast cancer after endocrine progression.

https://ja.ma/4rKeVhJ

03/31/2026

Incidentally detected spleen length ≥140 mm or volume ≥500 mL was associated with markedly elevated 5-year risk for hematologic cancer, liver cancer, and cirrhosis in adults from Denmark and the UK.

This cohort study evaluates relative and absolute risks of hematologic cancers, cirrhosis, and liver cancer according to spleen length and volume in individuals with incidentally detected splenomegaly.

03/30/2026

The 2025 federal restrictions are projected to cause over 1 million missed exams and over 150 excess deaths within 2 years, with substantial impact on younger and vulnerable adults. https://ja.ma/4ca3YkS

03/29/2026

💬 Editorial by Asona Lui, MD, PhD, and Charles R. Thomas Jr, MD:

Stereotactic radiation offered modest symptom relief and better long-term neurocognitive outcomes than hippocampal-avoidance whole brain radiation, but was associated with higher rates of new brain metastases and salvage whole brain radiotherapy.

https://ja.ma/4ccsm5l

03/29/2026

From JAMA: The Medicare Care Model (OCM) was associated with modest reductions in Medicare payments for beneficiaries receiving for cancer; however, overall program costs exceeded these spending reductions.

https://ja.ma/41ynC3X

03/29/2026

Guideline-adherent lymph node dissection provided a small survival benefit for patients with high-grade or no lepidic pattern , but not for those with lepidic pattern alone. https://ja.ma/4lV2vSZ

03/28/2026

When lung cancer has spread beyond the lungs, this is known as stage IV (4), or metastatic, lung cancer.

Treatment at this stage usually focuses on systemic therapy, medications prescribed by a medical oncologist, such as targeted therapy, immunotherapy, antibody-drug conjugates, or chemotherapy, that travel through the bloodstream to treat cancer cells throughout the body.

📄 This JAMA Oncology Patient Page discusses benefits and risks of local consolidative therapy for metastatic and which patients might be considered for this treatment.

https://ja.ma/4uU13UK